non small cell lung cancer
Conditions
Interventions
Patients receive CBDCA (AUC 2) and nab-paclitaxel (35, 40, 45mg/m2) on day 1 every weeks with concurrent thoracic radiation therapy.
Sponsors
Kochi University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histologically or cytologically comfirmed non-small cell lung cancer 2) patient has an indication for concurrent chemoradiotherapy. 3) ECOG performance status of 0-2 4) patients aged 20 years or older 5) adequate bone marrow, liver, and renal functions 2weeks prior to registration: neutorophil >=1,500/mm3; platelet >=100,000/mm3; AST and ALT < 5x of upper limit of normal (ULN); total bilirubin <=1.5mg/mL; serum creatinin <=1.5 mg/dl; SpO2>90 6) a life expectancy of 3 months or more 7) written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, radiation pneumonitis, or drug-induced lung damage 2) complicated by infectious disease requiring intravenous administration of antifungal agents and/or antibacterial agents 3) active double cancer 4) Patients with problematic complication(s) (ex. uncontrol heart disease, serious arrhythmia) 5) pregnant or lactating women or those who declined contraception 6) Patients with severe mental illness 7) Unsuitable patients judged by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of the recommended dose, evaluation of dose-limiting toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| safety and efficacy | — |
Countries
Japan
Contacts
Public ContactTetsuya Kubota
Kochi University, School of Medicine Dept of Hematology and Respiratory Medicine
Outcome results
None listed